BRADBURY DANIEL 4

What Happened

• Daniel Bradbury, a director of Castle Biosciences (CSTL), received a grant of 11,766 Restricted Stock Units (RSUs) on May 28, 2026. The filing reports $0.00 paid for the award (derivative grant), meaning no cash changed hands at grant.

Key Details

• Transaction type/date: Award/Grant (code A) on 2026-05-28; reported on Form 4 filed 2026-06-01.
• Shares/price: 11,766 RSUs granted at $0.00 (RSUs are derivative awards).
• Shares owned after transaction: Not specified in the supplied filing summary — see the full Form 4 for total beneficial ownership.
• Vesting (footnotes): Each RSU converts to one common share. Vesting in full on the earlier of (a) the one‑year anniversary (May 28, 2027) or (b) the day before the next Annual Meeting of stockholders following the grant.
• Timeliness: Form 4 was filed 2026-06-01. Form 4s are generally due within two business days of the transaction; this filing appears to have been submitted one business day after that window.

Context

• RSUs are a common form of equity compensation for directors and typically convert to shares upon vesting; they are not an immediate cash purchase or sale. Grants indicate compensation but do not by themselves signal a buy or sell decision in the market.